Geode Capital Management LLC Sells 52,942 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

Geode Capital Management LLC cut its position in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 4.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,280,567 shares of the biopharmaceutical company’s stock after selling 52,942 shares during the quarter. Geode Capital Management LLC’s holdings in Regulus Therapeutics were worth $2,011,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the company. Barclays PLC boosted its holdings in Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 62,549 shares during the period. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics in the third quarter valued at about $46,000. State Street Corp lifted its stake in shares of Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock valued at $1,572,000 after buying an additional 33,496 shares during the period. Point72 Asset Management L.P. acquired a new stake in Regulus Therapeutics during the third quarter worth about $1,403,000. Finally, NEA Management Company LLC bought a new position in Regulus Therapeutics during the third quarter valued at about $10,154,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Trading Down 1.3 %

RGLS stock opened at $1.49 on Thursday. The stock has a 50-day moving average price of $1.54 and a two-hundred day moving average price of $1.61. Regulus Therapeutics Inc. has a 1 year low of $1.08 and a 1 year high of $3.79. The stock has a market cap of $97.60 million, a PE ratio of -1.39 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RGLS shares. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Regulus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.